rs12487736 — SCAP SCAP Val798Ile

Missense variant in the SCAP cholesterol-sensor gene (Val798Ile); the C allele (coding-strand G) impairs the SCAP–SREBP-2 feedback axis, promoting cholesterol accumulation in vascular cells and elevating sudden cardiac death risk in combination with the SREBF2 Gly595Ala variant

See your personal result for SCAP

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SCAP Val798Ile — The Cholesterol-Sensor Variant at the Heart of Plaque Formation

Before a cell can respond to low cholesterol by making more, it needs to sense the deficit. That sensing job belongs to SCAP (SREBP cleavage-activating protein)11 SCAP (SREBP cleavage-activating protein)
a seven-transmembrane sterol-sensing protein in the ER membrane that escorts SREBP transcription factors to the Golgi for proteolytic activation. When cholesterol is plentiful, SCAP is detained at the ER by INSIG proteins. When cholesterol drops, SCAP escorts SREBP-2 to the Golgi, where it is cleaved and activated — driving LDL receptor and HMG-CoA reductase expression to restore cholesterol supply. The rs12487736 variant changes valine to isoleucine at position 798 of SCAP, sitting within the WD-repeat domain that contacts SREBP-2. This amino acid substitution may subtly alter SCAP's interaction geometry with SREBP-2 and its response to cholesterol feedback signals.

The Mechanism

The SCAP Val798Ile substitution lies in the carboxy-terminal WD40 repeat region of SCAP, which mediates direct protein-protein contact with SREBP-2's regulatory domain. The functional consequence of this change is not yet fully characterized at the structural level, but population and clinical data suggest it shifts the SCAP–INSIG–SREBP-2 axis toward a state that promotes vascular cholesterol accumulation. In genome-wide expression profiling of 20 human atherosclerotic plaque samples (carotid, aortic, femoral) versus 6 control vessel samples22 genome-wide expression profiling of 20 human atherosclerotic plaque samples (carotid, aortic, femoral) versus 6 control vessel samples
Fan et al., Thrombosis Journal, 2008, SREBF-2 mRNA was significantly downregulated in carotid plaques (p=0.02), suggesting that reduced SREBF-2 transcriptional activity in inflamed vascular tissue — potentially exacerbated by SCAP functional variants — is a feature of established atherosclerosis rather than a compensatory response.

Under inflammatory conditions, the mTOR pathway activates the SCAP–SREBP-2 complex, increasing its translocation from the ER to the Golgi and driving excess LDL receptor expression and cholesterol uptake into vascular cells. SCAP knockdown in smooth muscle cells of ApoE-/- mice33 SCAP knockdown in smooth muscle cells of ApoE-/- mice
Li et al., FASEB J, 2019 significantly reduced atherosclerotic plaque burden, confirming SCAP as a causal driver of lesion formation rather than merely a correlate. The rs12487736 variant, by modulating SCAP's functional state, may tilt this balance toward greater lipid accumulation in susceptible individuals — especially when co-inherited with functional variants in the SREBF2 gene itself.

The Evidence

The most compelling cardiovascular evidence comes from an autopsy-based study in 300 middle-aged Finnish men (ages 33–69) who died suddenly without prior diagnosed heart disease44 autopsy-based study in 300 middle-aged Finnish men (ages 33–69) who died suddenly without prior diagnosed heart disease
Fan et al., Thromb J, 2008. Researchers genotyped SCAP 2386A>G (rs12487736) and SREBF2 1784G>C (rs2228314) and correlated genotypes with coronary artery narrowing and lesion characteristics. On its own, the SCAP G allele (plus-strand C at rs12487736) did not reach independent significance for SCD risk. However, men carrying both the SCAP G allele and the SREBF2 C allele had a 2.68-fold elevated risk of sudden cardiac death (OR 2.68, 95% CI 1.07–6.71; interaction p=0.046), pointing to a gene-gene amplification effect when both components of the SCAP–SREBP-2 circuit carry functional variants simultaneously.

Population-level data reinforce the pathway's relevance. A case-control study in 1,801 Han Chinese adults55 A case-control study in 1,801 Han Chinese adults
Liu et al., Atherosclerosis, 2010 found three-locus interactions among SREBP2, SCAP, and INSIG1/2 variants significantly predicting coronary heart disease risk (p≤0.001). In pediatric cohorts, the variant also influences metabolic phenotypes: in 2,021 Chinese schoolchildren66 2,021 Chinese schoolchildren
Yang et al., PLoS One, 2017, rs12487736 was associated with both systolic BP (β=1.66, p=0.003) and diastolic BP (β=1.35, p=0.024), with a 36% elevated odds of high blood pressure in overweight/obese children carrying the risk allele (OR 1.36, 95% CI 1.02–1.82). The same variant interacts with dietary patterns to modulate blood pressure response, suggesting its effects are amplified under metabolic stress conditions.

A study of 614 HIV-positive individuals on antiretroviral therapy77 study of 614 HIV-positive individuals on antiretroviral therapy
Lazzaretti et al., ScientificWorldJournal, 2013 also found the variant significantly associated with HDL-cholesterol levels, consistent with SCAP's broad role in sterol balance across lipoprotein fractions.

Practical Actions

For CC homozygotes, the most actionable implication is the additive risk when combined with the SREBF2 C allele (rs2228314). Checking both variants together informs a meaningful risk stratification that neither variant achieves alone. The variant's effect on LDL receptor regulation makes it relevant to statin pharmacology: SCAP-mediated SREBP-2 activation is a key mechanism by which statins amplify LDLR transcription. Variants that blunt this relay may partially attenuate the LDL-lowering response to standard statin doses, though direct pharmacogenomic evidence for this specific variant remains sparse.

For individuals with overweight or obesity, this variant's interaction with metabolic burden on blood pressure is an additional reason to track both blood pressure and lipid levels systematically, as the variant appears to act as a conditional risk amplifier in the context of metabolic stress.

Interactions

The critical interaction is with SREBF2 rs2228314 (Gly595Ala). SCAP is the direct chaperone and sterol sensor for SREBP-2. When both SCAP (Val798Ile, rs12487736) and SREBP-2 (Gly595Ala, rs2228314) carry functional variants, the entire cholesterol-sensing circuit is doubly compromised — the sensor that detects cholesterol (SCAP) and the transcription factor it activates (SREBP-2) both function suboptimally. The 2.68-fold SCD risk in Finnish men demonstrates that this co-inheritance is clinically significant.

INSIG1 and INSIG2 variants at the same pathway node also interact with SCAP variants in determining coronary heart disease risk in Chinese cohorts — the INSIG–SCAP–SREBP axis behaves as an integrated cholesterol sensing unit whose aggregate genetic load matters more than any single variant.

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal

Standard SCAP cholesterol-sensor function

You carry two copies of the T allele (coding-strand A) at SCAP rs12487736, the common protective genotype. In European populations, approximately 33% of individuals share this genotype. Your SCAP protein carries the ancestral valine at position 798, maintaining the standard WD-repeat geometry for SREBP-2 interaction and cholesterol feedback. No elevated cardiovascular risk from this variant is expected based on current evidence.

CT Intermediate

One copy of the SCAP C allele — modest risk contribution to the cholesterol-sensing pathway

Most association studies for this variant have used dominant or additive models rather than isolating heterozygous effects. The blood pressure association studies (β=1.66 for systolic BP, β=1.35 for diastolic BP in the full cohort) enrolled both heterozygotes and homozygotes together, so the effect attributed to CT carriers specifically is diluted in these estimates. The HDL association in HIV/HAART patients also likely captures combined CT and CC effects. For heterozygotes, the key clinical relevance is the gene-gene interaction within the SCAP-SREBP-2 pathway — the 2.68-fold SCD risk requires functional variants at both loci.

CC High Risk

Homozygous SCAP C allele — elevated risk via impaired cholesterol-sensing feedback, especially in combination with SREBF2 variant

The SCAP protein's WD-repeat C-terminal domain physically contacts the regulatory domain of SREBP-2, facilitating ER-to-Golgi transport and proteolytic cleavage when cellular cholesterol is low. The Val798Ile change sits in this interaction region. While the variant's independent effect on SCD risk did not reach significance in the 300-sample Finnish autopsy study (likely insufficient power for single-variant analysis), the gene-gene interaction result (p=0.046 for the SCAP G × SREBF2 C combination) indicates that functional impairment at both ends of the sensing relay amplifies cardiovascular risk beyond what either variant contributes alone.

Expression profiling of atherosclerotic plaques from the same Finnish cohort found SREBF-2 mRNA significantly downregulated in carotid plaques versus control tissue (p=0.02), providing tissue-level evidence that the SCAP–SREBP-2 axis is suppressed in established vascular disease. Animal SCAP knockout models confirm that SCAP drives vascular foam cell formation, and that reducing SCAP activity in smooth muscle cells significantly decreases plaque burden — establishing SCAP as a causal atherosclerotic factor rather than a passive marker.

The blood pressure data (OR 1.36 in overweight children, β=1.66 for systolic BP) suggest a broader cardiometabolic footprint that compounds with traditional risk factors when metabolic stress is present.